Glaxo Group Limited

Glaxogrouplimited

Alexandre Eon-Duval

Jonathan Henry Ellis

Christopher Plumpton

Volker Germaschewski

Ruth McAdam

Nicholas Timothy Rapson

Rabinder Kumar Prinjha

Robert Ian Grundy

Paul Alexander Wilson

Michael Robert West

Farhana Hussain

The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.

NOGO-a neutralising immunoglobulin for treatment of neurological diseases

The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Immunoglobulins

Growing community of inventors

Fenil-Sur-Corsier, Switzerland

Alexandre Eon-Duval